284462-80-2Relevant articles and documents
ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
-
Paragraph 0196; 0197, (2016/02/12)
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
DIARYL UREAS AND COMBINATIONS
-
Page/Page column 45, (2008/06/13)
The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.
TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS
-
Page/Page column 11-12, (2012/04/23)
The present invention provides compositions and methods for treating cancers ; which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.